A selection of recent research publications

• Klabatsa A, Sheaff M, Steele JP, Evans M, Rudd R, Fennell D. Expression and prognostic significance of hypoxia inducible factor 1a (HIF-1a) in MPM
• Steele JP, Klabatsa A, Fennell DA, Pallaska A, Sheaff MT, Evans MT, Shamash J, Rudd RM. Prognostic factors in mesothelioma Lung Cancer. 2005 May 12; [Epub ahead of print]
• Steele JP and Klabatsa A. Chemotherapy options and new advances in malignant pleural mesothelioma. Annals of Oncology 2005;16:345-51
• Fennell DA, Steele JP, Shamash J, Sheaff MT, Evans MT, Goonewardene TI, Nystrom ML, Gower NH, Rudd RM. Phase II trial of vinorelbine and oxaliplatin as first-line therapy in malignant pleural mesothelioma. Lung Cancer 2005;47:277-81
• Fennell DA, Parmar A, Shamash J, Evans MT, Sheaff MT, Sylvester R, Dhaliwal K, Gower N, Steele J, Rudd R. Statistical validation of the EORTC prognostic model for malignant pleural mesothelioma based on three consecutive phase II trials. Journal of Clinical Oncology 2005;23:184-9
• Fennell DA and Rudd RM. Defective core-apoptosis signaling in diffuse malignant pleural mesothelioma: opportunities for effective drug development. Lancet Oncology 2004;5:354-62
• Steele JP. Prognostic factors in mesothelioma. Seminars in Oncology 2002; 29:36-40
• Steele JP, O'Doherty CA, Shamash J, Evans MT, Gower NH, Tischkowitz MD, Rudd RM. Phase II trial of liposomal daunorubicin in malignant pleural mesothelioma. Annals of Oncology 2001;12:497-9
• Steele JP, Shamash J, Evans MT, Gower NH, Tischkowitz MD, Rudd RM. Phase II study of vinorelbine in patients with malignant pleural mesothelioma. Journal of Clinical Oncology 2000;18:3912-7
• Steele JP and Rudd RM. Malignant mesothelioma: predictors of prognosis and clinical trials. Thorax 2000;55:725-6.